Merck and GSK to Remain Undefeated Market Leaders of US Cancer Vaccine Market, Finds RNCOS E-Services

01 Oct 2012 • by Natalie Aster

Cancer vaccines are highly researched today owing to growing cancer incidences and an urgent need to control and prevent the massively penetrating disease. Amongst the highest incident cancers, prostate cancers are high in males and breast cancer in females. The introduction of Merck’s Gardasil bought great attention to cancer vaccines. US represents the most promising market for cancer vaccines across the globe, accounting for around 49% share.

The prophylactic vaccines currently available in the market include Merck’s Gardasil, GSK’s Cervarix, and several other Hepatitis B vaccines while the only therapeutic vaccine in the market is Dendreon’s Provenge. The report “US Cancer Vaccine Market Analysis”, in such a scenario provides an analysis of the current market size for these vaccines along with future estimations. In-depth perspective has been provided for the various factors that will govern the growth of each of these vaccines along with the constraints that limit them.

Merck and GSK are expected to continue to be undefeated market leaders in the prophylactic cancer segment as the launch of a new cancer vaccine is unlikely in the next 3 years. The research and innovation for cancer vaccines is highly robust and several candidates are being studied for their role in cancer. Trials are focusing more on the therapeutic vaccines and this segment can be expected to evolve greatly in the years to come. Amongst the various studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as Lucanix and Stimuvax having entered phase 3 trials.

The new report “US Cancer Vaccine Market Analysis” by RNCOS E-Services covers the FDA's vaccine approval process and its guidance to the industry for developing therapeutic cancer vaccines. The therapeutic vaccines currently account only for about 15% share in the US cancer vaccine market but this share can be expected to increase drastically post 2016 with such high focus on developing therapeutics for other cancer types.

Report Details:

US Cancer Vaccine Market Analysis
Published: September, 2012
Pages: 135
Price: US$ 1.200,00

The report is an outcome of an extensive research and prudent analysis of the cancer vaccine market in the world and in US. It provides an effective analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Further, the report provides an in-depth analysis on the pipeline cancer vaccines in phase 1-4 clinical stages for most prevalent cancers in US. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines for clinical proceedings of cancer therapeutic vaccines has also been provided. The report also provides competitive analysis of the promising players in the market along with their key strategies to increase their penetration in the market.

More information can be found in the report “US Cancer Vaccine Market Analysis” by RNCOS E-Services.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com